ALK and non-small cell lung carcinoma: Following this study, in December 2018, the US FDA approved, atezolizumab+bevacizumab+paclitaxel+carboplatin for the front-line treatment of EGFR/ALK-negative metastatic nsq-NSCLC, regardless of PD-L1 expression status (69).